Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viemed Healthcare (VMD) Capital Expenditures (2018 - 2025)

Viemed Healthcare's Capital Expenditures history spans 8 years, with the latest figure at -$4.8 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 140.36% year-over-year to -$4.8 million; the TTM value through Sep 2025 reached $16.6 million, down 68.09%, while the annual FY2024 figure was $37.8 million, 44.76% up from the prior year.
  • Capital Expenditures reached -$4.8 million in Q4 2025 per VMD's latest filing, down from $819000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $26.1 million in Q4 2023 to a low of -$10.8 million in Q3 2022.
  • Average Capital Expenditures over 5 years is $4.4 million, with a median of $4.0 million recorded in 2022.
  • The largest YoY upside for Capital Expenditures was 5515.62% in 2021 against a maximum downside of 179600.0% in 2021.
  • A 5-year view of Capital Expenditures shows it stood at $6.7 million in 2021, then tumbled by 262.81% to -$10.8 million in 2022, then skyrocketed by 340.47% to $26.1 million in 2023, then tumbled by 54.65% to $11.8 million in 2024, then tumbled by 140.36% to -$4.8 million in 2025.
  • Per Business Quant, the three most recent readings for VMD's Capital Expenditures are -$4.8 million (Q4 2025), $819000.0 (Q3 2025), and $330000.0 (Q2 2025).